Success Stories


The Ultimate Validation of a Successful Randomized Clinical Trial

29 Tru-Ds Purchased to Date Among the BETR-D Hospitals

“I think it’s an important tool to have to prevent these infections from happening. All nine hospitals in the study, including our own here at Duke, have purchased these types of machines to continue to use even though the study has completed.”

Deverick Anderson, MD
BETR-D Researcher
Duke Health



Alamance Regional:
BETR-D Study Participant Hospital

While the facility already had one Tru-D robot, it invested in two additional units following the completion of the BETR-D Study. Overall, infections by superbugs have decreased by +12% at ARMC, and the goal is to reach zero infections through the use of Tru-D and other protective measures.



Chesapeake Regional Healthcare:
BETR-D Study Participant Hospital

Chesapeake Regional purchased four Tru-Ds after the BETR-D Study was complete. It experienced a significant decrease in both infection and colonization rates with all multidrug-resistant organisms (MDROs) and about a 12% decrease in C. diff infections during the arms of the study that included Tru-D units and bleach.

  • 1 Tru-d designated for OR
  • 3 Tru-Ds focused on C. diff
  • CRH longer monitors cleaning with pH pens
  • Focus on utilization resulted in infection reduction



There’s Clean and then There’s St. Jude Clean: St. Jude Children’s Research Hospital

Nearly every child at St. Jude has a fragile immune system and a high risk of acquiring infections. “That’s why it’s critical not just to follow minimal requirements, but to take steps above and beyond to provide another layer of protection around our patients.”

Hana Hakim, MD
Medical Director of St. Jude Infection Prevention and Control



University of Wisconsin Health: SHEA 2017

UW is serious about providing the safest environment for patient care including broad utilization of a sporicidal disinfectant, an established antibiotic stewardship program and a quality assurance program for monitoring cleaning of high touch surfaces. In 2016, a number of interventions were implemented anew or intensified if already in use to further lower hospital onset C. diff infection rates.  Among the interventions was the deployment of fourteen Tru-D SmartUVC UV disinfection robots which were implemented for all C. diff discharges. By the end of 2016, hospital onset C. diff dropped significantly.

  • 14 Tru-Ds purchased
  • Mandatory UV disinfection of all C. diff discharges
  • Multiple IP modalities previously implemented
  • Tru-D implementation had significant impact – 39% C. diff reduction


Lehigh Valley Health Network

An early adopter of Tru-D, Lehigh Valley has nine units among its campuses which has more than 1,000 beds. Deployed after every C. diff, norovirus and CRE discharge case, Lehigh Valley also utilizes the robots in its cardiac cath lab, burn units, labor and delivery rooms and radiology areas. Chosen for its Sensor360 technology, Lehigh Valley found that among competitors, Tru-D offered the greatest element of safety for its patients and staff, assuring every room is truly clean. Today, Tru-D continues to be an integral part of the Lehigh Valley environmental services team and a standard of care for every patient who walks in the door.



Sarasota Memorial Hospital

In the summer of 2014, Sarasota Memorial Hospital began to look at various enhanced cleaning technologies to add to its arsenal of cleaning strategies. With the onslaught of the Ebola breakout, the hospital ramped up its efforts to find a proactive solution to such infectious diseases and tested several UV disinfection robots. Due to its patented Sensor360 technology that analyzes a space and administers the proper, lethal dosage of UV light, Tru-D was selected as the device of choice. After implementing one Tru-D in its operating room, the hospital’s foundation purchased two additional units that are rotated throughout the hospital with a goal of disinfecting 100% of C. diff patients’ rooms.



Mission Hospital

Mission Hospital is currently using its Tru-D robots in its 16 ORs as well as in labor and delivery units. Last year, Mission only had one deep-organ SSI among all total hip cases. This is an “extremely significant drop,” according to Wendy Ferro-Grant. There have also been zero surgical site infections out of 330 total knee replacements. While she can’t attribute the sole reason for the drop to Tru-D, she’s confident it played a significant role.

St. Charles Bend

In January, St. Charles-Bend brought in Tru-D for a 45-day trial. Satisfied with the results of reducing hospital-acquired infections (HAIs) without impeding room turnovers, the hospital now intends to invest in three more units: one for the ORs; one for patient rooms on the medical floor; and one to be used as a floater where it’s needed most. “A lot of hospitals will shy away from buying high-ticket technology unless it brings in revenue, but this is an exception,” said Randy Barnes. “It has a patient safety benefit and essentially pays for itself.”

Bon Secours St. Mary’s — Richmond, VA

 Tru-D was brought in to clean patient discharge rooms at a doctor’s or nurse’s request. The robots also disinfects all 27 of St. Mary’s operating rooms twice a week. As one piece of a multi-level patient safety initiative, the arrival of Tru-D decreased surgical-site infections by 50 percent. More recently, Tru-D was used in 2017 to contain an outbreak of Klebsiella.“It is the right thing to do for our patients. Our patients deserve to have their surgeries at facilities that do their very best to reduce the risk of post-operative infections.”
– Khiet Trinh, M.D., chief medical officer at St. Mary’s

Yavapai Regional Medical Center
Prescott, AZ

Yavapai sought to establish a baseline of cleanliness throughout an entire wing of the hospital. For approximately 38 days, the focus was on all discharges in one unit that had experienced some ongoing transmission of C. diff. Since December 8, 2016 when the study concluded, there has not been a single, reported hospital-acquired infection in the hospital wing used in the trial. After the trial, Yavapai continues to use Tru-D with great success. On an ongoing basis, the focus will be on isolation discharge cases as the facility moves forward with establishing a baseline in other areas of the hospital.